AUTHORS
Yuanhua Cai, MD, PhD, Yingying Zeng2, Wei Ji, MD3, Zhixiang Chen, MD4, Jing Chen5, Peiyao Wang6, Yi Zheng7, Xiaolin Lai8, Yaping Wang9, Yang Li10, Lili Pan11, Qianglong Hong12, Jinggang Li13, Xiaofan Li Sr, MD, PhD14, Shaoyuan Wang15
AFFILIATIONS
1 Fujian Medical University Union Hospital, Fuzhou, China
2 Fujian Medical University Union Hospital, Fuzhou, China
3 Fujian Medical University Union Hospital, Fuzhou, China
4 Fujian Medical University Union Hospital, Fuzhou, China
5 Fujian Medical University Union Hospital, Fuzhou, China
6 Fujian Medical University Union Hospital, Fuzhou, China
7 Fujian Medical University Union Hospital, Fuzhou, China
8 Fujian Medical University Union Hospital, Fuzhou, China
9 Fujian Medical University Union Hospital, Fuzhou, China
10 Fujian Medical University Union Hospital, Fuzhou, China
11 Fujian Medical University Union Hospital, Fuzhou, China
12 Fujian Medical University Union Hospital, Fuzhou, China
13 Fujian Medical University Union Hospital, Fuzhou, China
14 Fujian Medical University Union Hospital, Fuzhou, China, Fujian Medical University Union Hospital, Fuzhou, China
15 Fujian Medical University Union Hospital, Fuzhou, China
ABSTRACT
DHX15R222G is a driver mutation exclusively identified in AML1-ETO-positive AML and is associated with adverse clinical outcomes, yet its functional role and molecular mechanism remain unknown.
To investigate the role of DHX15R222G, we generated CRISPR/Cas9-mediated knock-in models in AML1-ETO-positive AML cell lines (Kasumi-1 and SKNO-1). Although efficient genome editing and homology-directed repair were achieved shortly after editing, DHX15R222G-positive single-cell clones were not recovered, and mutant allele frequency progressively declined over time, suggesting that homozygous DHX15R222G acquisition is detrimental to AML cells. In contrast, lentiviral expression of DHX15R222G significantly enhanced leukemic cell fitness compared with wild-type DHX15, increasing cell viability, reducing apoptosis, and promoting colony formation in AML cell lines. Importantly, the survival advantage conferred by DHX15R222G was maintained in AML1-ETO-negative models and was not abolished by pharmacologic inhibition of AML1-ETO, demonstrating that DHX15R222G-mediated leukemia promotion is independent of AML1-ETO.
The oncogenic activity of DHX15R222G was further validated in vivo using cell line-derived xenograft models. Mice transplanted with DHX15R222G-expressing U937 cells demonstrated significantly shortened overall survival, increased peripheral leukemic burden, elevated white blood cell counts, reduced hemoglobin levels, and enhanced leukemic infiltration compared with DHX15WT controls. These data suggest that DHX15R222G promotes AML development in vivo.
To study the underlying mechanism of R222G on splicing factor DHX15, Oxford Nanopore long-read RNA sequencing (ONT-seq) was performed in AML cell lines and primary AML samples. DHX15R222G induced widespread alterations in transcript diversity and alternative splicing patterns, with predominant changes in exon skipping and alternative first exon usage. Differential transcript analysis identified 455 upregulated and 510 downregulated transcripts in AML cell lines and 3,264 upregulated and 3,309 downregulated transcripts in primary AML cells. Gene ontology analysis revealed enrichment of RNA processing and mRNA splicing pathways, indicating that DHX15R222G remodels the RNA regulatory landscape of AML.
To further investigate the downstream RNA that DHX15R222G interacted with, RNA immunoprecipitation sequencing (RIP-seq) was performed. The result showed extensive remodeling of the DHX15 RNA interactome, with 372 RNAs showing increased binding and 859 RNAs showing decreased binding compared with controls. Further metagene analysis showed distinct enriched motifs in the presence of R222G. DHX15R222G bound motifs with extended or altered core sequences, such as GAAGA, UACA, AAAAGAAAA, CACASC, and CCGGA. Collectively, these data indicate that the R222G rewires the RNA-binding motifs of DHX15, leading to widespread changes in target RNA binding and associated cellular pathways in AML. Integrated analysis of ONT-seq, RIP-seq, and proteomic datasets identified CAST (calpastatin) as a conserved downstream target. DHX15R222G selectively weakened DHX15 binding to CAST pre-mRNA, disrupting exon-skipping regulation and reducing CAST transcript and protein expression.
Collectively, these findings identify DHX15R222G as a leukemia-promoting mutation that reshapes RNA processing by altering DHX15 RNA-binding specificity and inducing aberrant alternative splicing. These results reveal a previously unrecognized mechanism of AML evolution and highlight mutant DHX15-dependent regulation of RNA splicing as a potential therapeutic vulnerability.
DISCLOSURES
Yuanhua Cai, MD, PhD: No relevant conflicts of interest to declare.